Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.35 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.35 |
| ▸ | ITGAV | P06756 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.35 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.35 |
| ▸ | ITGAL | P20701 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8178098 | 0.77 | HSD17B10 (0.55) | MAP3K14MEN1APEX1KMT2ATDP1 | |
| SCHEMBL21658858 | 0.76 | MAP3K14 (0.46) | MAP3K14MEN1APEX1KMT2ATDP1 | |
| SCHEMBL28384945 | 0.76 | LMNA (0.39) | MAP3K14MEN1APEX1KMT2ATDP1 | |
| SCHEMBL2711511 | 0.74 | MAP3K14 (0.44) | MAP3K14MEN1APEX1KMT2ATDP1 | |
| SCHEMBL514603 | 0.74 | ALDH1A1 (0.52) | MAP3K14MEN1APEX1KMT2ATDP1 | |
| SCHEMBL6654363 | 0.73 | MAP3K14 (0.33) | MAP3K14ALDH1A1HSD17B10CRBNLMNA | |
| SCHEMBL17941775 | 0.73 | FAAH (0.36) | MAP3K14ALDH1A1HSD17B10LMNA | |
| SCHEMBL2100563 | 0.73 | LMNA (0.51) | L3MBTL1ALDH1A1HSD17B10LMNAMAPT | |
| SCHEMBL6511682 | 0.72 | MAP3K14 (0.43) | MAP3K14MEN1APEX1KMT2ATDP1 | |
| SCHEMBL2896147 | 0.72 | MEN1 (0.47) | MAP3K14MEN1APEX1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1049678-B1 | CYCLOHEXYL AND HETEROCYCLYL NUCLEOSIDE DERIVATIVES, METHOD FOR PRODUCING THESE DERIVATIVES, AND THE USE OF THE DERIVATIVES AND THEIR OLIGOMERS OR CONJUGATES IN PAIRING AND/OR TESTING SYSTEMS | SANOFI SA (FR) | 2012-10-24 | — | — | EP | claimed |
| US-7439345-B2 | Supramolecular pairing system, its preparation and use | NANOGEN RECOGNOMICS GMBH (DE) | 2008-10-21 | — | — | US | claimed |
| US-10370652-B2 | Methods of nucleic acid amplification and sequencing | ILLUMINA, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20160319274-A1 | Methods of Nucleic acid amplification and sequencing | ILLUMINA, INC. (US) | 2016-11-03 | — | — | US | disclosed |
| US-9297006-B2 | Methods of nucleic acid amplification and sequencing | ILLUMINA, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20140228254-A1 | Methods of Nucleic acid amplification and sequencing | ILLUMINA, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-8652810-B2 | Methods of nucleic acid amplification and sequencing | ILLUMINA, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| EP-1634963-B1 | Method of nucleic acid amplification using immobilised colony primers | ILLUMINA CAMBRIDGE LTD (GB) | 2013-06-19 | — | — | EP | disclosed |
| WO-2013074632-A1 | MISMATCH NUCLEOTIDE PURIFICATION AND IDENTIFICATION | ROSE FLOYD D (US) | 2013-05-23 | — | — | WO | disclosed |
| US-20100285970-A1 | METHODS OF SEQUENCING NUCLEIC ACIDS | ROSE FLOYD D | 2010-11-11 | — | — | US | disclosed |
| EP-1117827-B8 | METHODS OF NUCLEIC ACID AMPLIFICATION AND SEQUENCING | SOLEXA LTD (GB) | 2010-06-02 | — | — | EP | disclosed |
| US-20080160580-A1 | Methods of nucleic acid amplification and sequencing | SOLEXA, INC | 2008-07-03 | — | — | US | disclosed |
| US-7115400-B1 | Methods of nucleic acid amplification and sequencing | SOLEXA LTD. (GB) | 2006-10-03 | — | — | US | disclosed |
| EP-1634963-A1 | Methods of nucleic acid amplification and sequencing | Solexa Ltd. (GB) | 2006-03-15 | — | — | EP | disclosed |
| EP-1117827-B1 | METHODS OF NUCLEIC ACID AMPLIFICATION AND SEQUENCING | SOLEXA LTD (GB) | 2005-11-30 | — | — | EP | disclosed |
| US-20040142451-A1 | Supramolecular pairing system, its preparation and use | NANOGEN RECOGNOMICS GMBH (DE) | 2004-07-22 | — | — | US | disclosed |
| US-6689884-B1 | Supramolecular pairing system, its preparation and use | NANOGEN RECOGNOMICS GMBH (DE) | 2004-02-10 | — | — | US | disclosed |
| CN-1325458-A | Nucleic Acid Amplification and Sequencing Methods | APPLIED RES SYSTEM ARS HOLDING (NL) | 2001-12-05 | — | — | CN | disclosed |
| EP-1117827-A1 | METHODS OF NUCLEIC ACID AMPLIFICATION AND SEQUENCING | Applied Research Systems ARS Holding N.V. (AN) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000018957-A1 | METHODS OF NUCLEIC ACID AMPLIFICATION AND SEQUENCING | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142451-A1 | Supramolecular pairing system, its preparation and use | TIMCC, MTCL3, UACA | MAP3K14 4550/4885MEN1 348/4885APEX1 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.